Guggenheim Begins Coverage on Sionna Therapeutics (NASDAQ:SION)

Equities research analysts at Guggenheim started coverage on shares of Sionna Therapeutics (NASDAQ:SION) in a report issued on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $45.00 price target on the stock. Guggenheim’s price target indicates a potential upside of 173.06% from the company’s current price.

Sionna Therapeutics Stock Up 11.4 %

Shares of NASDAQ:SION opened at $16.48 on Tuesday. Sionna Therapeutics has a 1 year low of $13.20 and a 1 year high of $25.19.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.